[
  {
    "ts": null,
    "headline": "DexCom Inc. stock outperforms competitors despite losses on the day",
    "summary": "DexCom Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=d7df58d0787a75b68713f8713fdff06f36610b0467a6c35e1e1a12a2adba123a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760547600,
      "headline": "DexCom Inc. stock outperforms competitors despite losses on the day",
      "id": 137149185,
      "image": "",
      "related": "DXCM",
      "source": "MarketWatch",
      "summary": "DexCom Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=d7df58d0787a75b68713f8713fdff06f36610b0467a6c35e1e1a12a2adba123a"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For DexCom (DXCM) Could Change Following Cautious Full-Year Outlook Amid Sector Selloff",
    "summary": "Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by worsened US-China trade tensions. While DexCom’s quarterly results highlighted robust product demand, the company’s cautious guidance stood in contrast to more optimistic updates from some competitors, pointing to sector-specific and company-level headwinds. We’ll now consider how DexCom’s...",
    "url": "https://finnhub.io/api/news?id=b0707c950b0a854fbd142259ca6cef56b59806f492a23c08978f086a996175e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760504957,
      "headline": "The Bull Case For DexCom (DXCM) Could Change Following Cautious Full-Year Outlook Amid Sector Selloff",
      "id": 137095998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by worsened US-China trade tensions. While DexCom’s quarterly results highlighted robust product demand, the company’s cautious guidance stood in contrast to more optimistic updates from some competitors, pointing to sector-specific and company-level headwinds. We’ll now consider how DexCom’s...",
      "url": "https://finnhub.io/api/news?id=b0707c950b0a854fbd142259ca6cef56b59806f492a23c08978f086a996175e7"
    }
  }
]